{"contentid": 488095, "importid": NaN, "name": "Janssen\u00e2\u0080\u0099s Ponvory approved after beating competitor in trial", "introduction": "The US Food and Drug Administration (FDA) has approved Ponvory (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.", "content": "<p>The US Food and Drug Administration (FDA) has approved Ponvory (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.</p>\n<p>This approval is based, in part, on a two-year, head-to-head Phase III trial in which Ponvory 20mg demonstrated superior efficacy in significantly reducing annual relapses by 30.5% compared to teriflunomide 14mg in patients with relapsing MS.</p>\n<p>Teriflunomide, sold by Sanofi (Euronext: SAN) under the name Aubagio, has been approved in the USA since 2012 and in Europe from the following year.</p>\n<p>In the comparative trial, 71% of patients treated with Ponvory had no confirmed relapses in the study period, compared to 61% in the teriflunomide group.</p>\n<p>Ponvory was also superior to teriflunomide<sup>&nbsp;</sup>in reducing the number of new gadolinium-enhancing T1 lesions and the number of new or enlarging T2 lesions by 59% and 56%, respectively.</p>\n<p>Mathai Mammen is global head of Janssen Research &amp; Development, part of US healthcare giant Johnson &amp; Johnson (NYSE: JNJ), the company developing Ponvory.</p>\n<p>He said: \"Every person with MS is affected differently, given variability in both the underlying disease and emerging symptoms. Continued innovation in this space is critical, and we're committed to meeting patients' evolving healthcare needs.</p>\n<p>\"We are proud to offer Ponvory as a valuable new option for people with MS that may help them gain better control of their disease.\"</p>\n<p>Janssen submitted a Marketing Authorization Application to the European Medicines Agency for ponesimod for treatment of adults with relapsing multiple sclerosis in the first quarter of 2020, and it remains under review.</p>\n<p>&nbsp;</p>", "date": "2021-03-19 14:49:00", "meta_title": NaN, "meta_keywords": "Ponvory, disease, approved, relapsing, trial, sclerosis, multiple, adults, teriflunomide, ponesimod, Janssen\u00e2\u0080\u0099s, competitor, beating, active, progressive", "meta_description": "The US Food and Drug Administration (FDA) has approved Ponvory (ponesimod).a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator.to tr", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-19 14:24:19", "updated": "2021-03-19 15:18:47", "access": NaN, "url": "https://www.thepharmaletter.com/article/janssen-s-ponvory-approved-after-beating-competitor-in-trial", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "janssen_ponvory_large.png", "image2id": "janssen_ponvory_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Hematology, Oncology", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "USA", "company_tag": "Janssen, Johnson & Johnson", "drug_tag": "ponesimod, Ponvory", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-19 14:49:00"}